Research reveals new bioactive compounds from Cistus salvifolius herb extract inhibiting COX enzymes in vitro, indicating potential therapeutic uses.
Two new proanthocyanidins, epigallocatechin-3-O-p-hydroxybenzoate-(4β→8)-epigallocatechin (1) and epigallocatechin-3-O-p-hydroxybenzoate-(4β→8)-epigallocatechin-3-O-gallate (2) in addition to the known compound epigallocatechin-(4β→6)-epigallocatechin-3-O-gallate (3), were isolated from the air-dried herb of Cistus salvifolius. The chemical structures were determined on the basis of 1D-and 2D-NMR-spectra (HSQC, HMBC) of their peracetylated derivatives, MALDI-TOF-mass spectra, and by acid-catalysed degradation with phloroglucinol. The isolated compounds 1–3 and the water extract of C. salvifolius herb were tested for their inhibitory activities against COX-1 and COX-2. Compound 2 showed the strongest inhibitory effect on COX-2 followed by compound 3, compound 1 and the water extract, while compounds 1–3 exhibited moderate in vitro inhibition against COX-1.
No takes yet. Share an insight, caveat, or question.
Qa'dan et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: